Proposed Phase II Trial Aims to Explore Optune System in Grade III Recurrent Glioma

Excerpt:

“Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.

“Daniel O’Connell, MD, a neuro-oncologist at UCLA’s Geffen School of Medicine, discussed his proposal with Targeted Oncology at the 21st Annual Scientific Meeting of the Society of Neuro-Oncology (SNO) held November 17 to 20, 2016 in Scottsdale, Arizona.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.